Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators
Report Package Immuno-Oncology: Inhibitory and Stimulatory Immunomodulators
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:
Negative Immune Checkpoints:
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
This product consists of four reports in pdf format describing the competitive field of new molecular entities directed against inibitory as well stimulatory immune checkpoints on T-cells, antigen presenting cells (APCs)/dendritic cells or tumor cells and against immunosuppressive factors in the tumor microencironment, including Treg cells, tumor-associated macrophages (TAM), myeloid derived suppressor cells (MDSC).
Each of the four reports can be obtained individually, but the package of the four reports provides a 40% discount on the regular prices:
- Competitor Analysis: PD-1 and PD-L1 Immune Checkpoint Inhibitors 2018
- Competitor Analysis: CTLA-4, LAG-3, TIM-3, TIGIT & Other Immune Checkpoint Inhibitors 2018
- Competitor Analysis: CD40, GITR, OX40, 4-1BB, CD27, ICOS & Other Immune Checkpoint Activators 2018
- Competitor Analysis: Tumor Microenvironment Modulation via IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, adenosine pathway & STING 2018
Negative Immune Checkpoints:
- PD-1 (programmed cell death 1)
- PD-L1 (programmed cell death ligand 1 (PD-L1)
- CTLA-4 (Cytotoxic T-Lymphocyte-Associated Protein-4; CD152)
- LAG-3 (Lymphocyte Activation Gene 3; CD223)
- TIM-3 (T-cell Immunoglobulin domain and Mucin domain 3; HAVCR2)
- TIGIT (T-cell Immunoreceptor with Ig and ITIM domains)
- B7-H3 (CD276)
- Others (VISTA: V-region Ig-containing Suppressor of T-cell Activation; BTLA: B- and T-Lymphocyte Attenuator; GARP: Glycoprotein A Repetitions Predominant; PVRIG; B7-H4)
- CD40 (TNFSFR5)
- GITR (Glucocorticoid-Induced Tumor Necrosis Factor Receptor; TNFSFR18)
- OX40 (CD134; TNFSFR4)
- 4-1BB (CD137; TNFSFR9)
- CD27 (TNFSFR7)
- ICOS (Inducible Co-Stimulator)
- IDO (Indoleamine 2,3-dioxygenase
- TDO (Tryptophan 2,3 dioxygenase)
- TGF-?/R (Transforming Growth Factor beta/Receptor)
- CXCR4 (Chemokine Receptor Type 4) & othe novel chemokines/receptors
- CSF-1R (Colony Stimulating Factor-1 Receptor)
- CD47 – SIRP? (Signal Regulatory Protein Alpha)
- Adenosine Pathway: Adenosine 2A Receptor (A2AR), CD73, CD39 & adenosine
- STING (STimulator of INterferon Genes) Receptor
- Others (e.g. arginase)
The reports include compilations of currently active projects in research and development of immunomodulators in immuno-oncology. In addition, each report lists company-specific R&D pipelines of cancer immunomodulators. Competitor projects are listed in a tabular format providing information on:
- Drug Codes,
- Target/Mechanism of Action,
- Class of Compound,
- Company,
- Product Category,
- Indication,
- R&D Stage and
- additional comments with a hyperlink leading to the source of information.
The Competitor Analysis Series delivers NO-FRILLS, but concise information about the pipeline of R&D projects for targets, diseases, technologies and companies at low prices. The information is provided in a tabular format and fully referenced.
REPORT 1: PD-1 AND PD-L1 IMMUNE CHECKPOINT INHIBITORS 2018
1a) PD-1 Receptor Antagonists:
Approved and Marketed PD-1 Antagonists
Specific PD-1 Antagonists in Clinical Development for Regulated Markets
Bispecific PD-1 Antagonists in Clinical Development for Regulated Markets
Specific PD-1 Antagonists in Clinical Development for Less Regulated Markets
Specific PD-1 Antagonists in Non- or Pre-Clinical Development
Bispecific PD-1 Antagonists in Non- or Pre-Clinical Development
1b) PD-L1 Inhibitors:
Approved and Marketed PD-L1 Inhibitors
Specific PD-L1 Inhibitors in Clinical Development for Regulated Markets
Bispecific PD-L1 Inhibitors in Clinical Development for Regulated Markets
Specific PD-L1 Inhibitors in Clinical Development for Less Regulated Markets
Specific PD-L1 Inhibitors in Non- and Preclinical Development
Bi-and Multi-Specific PD-L1 Inhibitors in Non- and Preclinical Development
2) CORPORATE PD-1 AND PD-L1 CHECKPOINT INHIBITOR R&D PIPELINES
REPORT 2: CTLA-4, LAG-3, TIM-3, TIGIT & OTHER IMMUNE CHECKPOINT INHIBITORS 2018
1a) CTLA-4 Receptor Antagonists:
Selective CTLA-4 Antagonist in Clinical Development in Regulated Markets
Selective CTLA-4 Antagonist in Clinical Development in Less Regulated Markets
Bispecific CTLA-4 Antagonist in Clinical Development
Selective or Bispecific CTLA-4 Antagonists in Non-Clinical Development
Selective or Bispecific CTLA-4 Antagonist in Preclinical R&D
1b) LAG-3 Antagonists:
Relatlimab Pipeline
Selective LAG-3 Antagonists in Clinical Development
Bispecific LAG-3 Antagonists in Clinical Development
LAG-3 Antagonists in Non-Clinical Development
LAG-3 Antagonists in Preclinical R&D
1c) TIM-3 Antagonists:
Selective and Bispecific TIM-3 Antagonists in Clinical Development
Selective and Bispecific TIM-3 Antagonists in Non-Clinical Development
TIM-3 Antagonists in Preclinical R&D
1d) TIGIT Antagonists:
TIGIT Antagonists in Clinical Development
TIGIT Antagonists in Non-Clinical Development
TIGIT Antagonists in Preclinical R&D
1e) Other Inhibitors of Negative Immune Checkpoints
B7-H3 Targeted Immune Checkpoint Inhibitors
Inhibitors of Other Immune Checkpoints
2) CORPORATE INHIBITORS OF NEGATIVE IMMUNE CHECKPOINTS R&D PIPELINES
REPORT 3: CD40, GITR, OX40, 4-1BB, CD27, ICOS & OTHER IMMUNE CHECKPOINT ACTIVATORS
CD40 Agonists
GITR Agonists
OX40 Agonists
4-1BB (CD137) Agonists
CD27 Agonists1f) ICOS Agonists
Other Immune Checkpoint Activators
2) CORPORATE IMMUNE CHECKPOINT ACTIVATOR R&D PIPELINES
REPORT 4: TUMOR MICROENVIRONMENT MODULATION VIA IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, ADENOSINE PATHWAY & STING 2018
1a) IDO & TDO Inhibitors
First-Generation Selective IDO-1 Inhibitors
Novel Selective IDO-1 Inhibitors
Dual IDO/TDO Inhibitors
Selective TDO Inhibitors
Other Approaches for IDO or TDO Inhibition
1b) TGF-beta Inhibitors
Indirect TGF-beta Inhibition
Selective TGF-beta1 Inhibitors
Selective TGF-beta2 Inhibitors
Dual or Triple TGF-beta Inhibitors
Bispecific TGF-beta Inhibition
1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors
CXCR4 Antagonists
CXCL12/SDF-1 Inhibitors
1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists
Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
Other Interleukin Inhibitors
CCR2/CCR5 Antagonists
CCR4 Antagonists
1e) CSF-1R Antagonists & CSF-1 Inhibitors
Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
Selective CSF-1R Antagonists and CSF-1 Inhibitors
1f) CD47 Antagonists & SIRPalpha Inhibitors
CD47 Antagonists
SIRP? Inhibitors
Bispecific CD47 Antagonists
1g) Adenosine Pathway Modulation
Selective Adenosine A2A Receptor Antagonists
Selective Adenosine A2B Receptor Antagonists
Dual Adenosine A2 Receptor Antagonists
CD73 Ectoenzyme Inhibitors
CD39 Ectoenzyme Inhibitors
Other Approaches
1h) STING Agonists
2) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES
1a) PD-1 Receptor Antagonists:
Approved and Marketed PD-1 Antagonists
Specific PD-1 Antagonists in Clinical Development for Regulated Markets
Bispecific PD-1 Antagonists in Clinical Development for Regulated Markets
Specific PD-1 Antagonists in Clinical Development for Less Regulated Markets
Specific PD-1 Antagonists in Non- or Pre-Clinical Development
Bispecific PD-1 Antagonists in Non- or Pre-Clinical Development
1b) PD-L1 Inhibitors:
Approved and Marketed PD-L1 Inhibitors
Specific PD-L1 Inhibitors in Clinical Development for Regulated Markets
Bispecific PD-L1 Inhibitors in Clinical Development for Regulated Markets
Specific PD-L1 Inhibitors in Clinical Development for Less Regulated Markets
Specific PD-L1 Inhibitors in Non- and Preclinical Development
Bi-and Multi-Specific PD-L1 Inhibitors in Non- and Preclinical Development
2) CORPORATE PD-1 AND PD-L1 CHECKPOINT INHIBITOR R&D PIPELINES
REPORT 2: CTLA-4, LAG-3, TIM-3, TIGIT & OTHER IMMUNE CHECKPOINT INHIBITORS 2018
1a) CTLA-4 Receptor Antagonists:
Selective CTLA-4 Antagonist in Clinical Development in Regulated Markets
Selective CTLA-4 Antagonist in Clinical Development in Less Regulated Markets
Bispecific CTLA-4 Antagonist in Clinical Development
Selective or Bispecific CTLA-4 Antagonists in Non-Clinical Development
Selective or Bispecific CTLA-4 Antagonist in Preclinical R&D
1b) LAG-3 Antagonists:
Relatlimab Pipeline
Selective LAG-3 Antagonists in Clinical Development
Bispecific LAG-3 Antagonists in Clinical Development
LAG-3 Antagonists in Non-Clinical Development
LAG-3 Antagonists in Preclinical R&D
1c) TIM-3 Antagonists:
Selective and Bispecific TIM-3 Antagonists in Clinical Development
Selective and Bispecific TIM-3 Antagonists in Non-Clinical Development
TIM-3 Antagonists in Preclinical R&D
1d) TIGIT Antagonists:
TIGIT Antagonists in Clinical Development
TIGIT Antagonists in Non-Clinical Development
TIGIT Antagonists in Preclinical R&D
1e) Other Inhibitors of Negative Immune Checkpoints
B7-H3 Targeted Immune Checkpoint Inhibitors
Inhibitors of Other Immune Checkpoints
2) CORPORATE INHIBITORS OF NEGATIVE IMMUNE CHECKPOINTS R&D PIPELINES
REPORT 3: CD40, GITR, OX40, 4-1BB, CD27, ICOS & OTHER IMMUNE CHECKPOINT ACTIVATORS
CD40 Agonists
GITR Agonists
OX40 Agonists
4-1BB (CD137) Agonists
CD27 Agonists1f) ICOS Agonists
Other Immune Checkpoint Activators
2) CORPORATE IMMUNE CHECKPOINT ACTIVATOR R&D PIPELINES
REPORT 4: TUMOR MICROENVIRONMENT MODULATION VIA IDO, TGF-?, CXCR4, CSF-1R, CD47-SIRP?, ADENOSINE PATHWAY & STING 2018
1a) IDO & TDO Inhibitors
First-Generation Selective IDO-1 Inhibitors
Novel Selective IDO-1 Inhibitors
Dual IDO/TDO Inhibitors
Selective TDO Inhibitors
Other Approaches for IDO or TDO Inhibition
1b) TGF-beta Inhibitors
Indirect TGF-beta Inhibition
Selective TGF-beta1 Inhibitors
Selective TGF-beta2 Inhibitors
Dual or Triple TGF-beta Inhibitors
Bispecific TGF-beta Inhibition
1c) CXCR4 Antagonists & CXCL2/SDF-1 Inhibitors
CXCR4 Antagonists
CXCL12/SDF-1 Inhibitors
1d) Novel Chemokine Inhibitors & Chemokine Receptor Antagonists
Interleukin-8/CXCL8 Inhibitors & CXCR2/CXCR1 Antagonists
Other Interleukin Inhibitors
CCR2/CCR5 Antagonists
CCR4 Antagonists
1e) CSF-1R Antagonists & CSF-1 Inhibitors
Multi-Specific CSF-1R Tyrosine Kinase Inhibitors
Selective CSF-1R Antagonists and CSF-1 Inhibitors
1f) CD47 Antagonists & SIRPalpha Inhibitors
CD47 Antagonists
SIRP? Inhibitors
Bispecific CD47 Antagonists
1g) Adenosine Pathway Modulation
Selective Adenosine A2A Receptor Antagonists
Selective Adenosine A2B Receptor Antagonists
Dual Adenosine A2 Receptor Antagonists
CD73 Ectoenzyme Inhibitors
CD39 Ectoenzyme Inhibitors
Other Approaches
1h) STING Agonists
2) CORPORATE TUMOR MICROENVIRONMENT MODULATOR R&D PIPELINES
